CT引导联合3D打印非共面模板辅助125I粒子植入治疗局部复发直肠癌的疗效与剂量学分析
本研究回顾性纳入66例术后或外照射放疗后局部复发直肠癌患者,采用CT引导联合3D打印非共面模板辅助125I粒子植入治疗。中位随访12.2个月,中位总生存14.7个月,中位局部控制12.2个月,85.1%患者疼痛缓解,9.1%出现≥3级严重不良反应。D90>130 Gy或D100>55 Gy或V100>90%时局部控制时间显著延长,但均未显著影响总生存。
要点
- CT引导联合3D打印非共面模板辅助125I粒子植入是术后或外照射后局部复发直肠癌的有效安全挽救治疗。
- D90>130 Gy或D100>55 Gy或V100>90%时局部控制时间显著延长,可作为预后预测指标。
- 85.1%患者疼痛缓解,9.1%出现≥3级严重不良反应。
核心结论
- CT引导联合3D打印非共面模板辅助125I粒子植入是术后或外照射放疗后局部复发直肠癌的有效且安全的挽救治疗策略。
- D90、D100和V100可作为预后预测指标。
研究设计与样本
- 回顾性纳入2015年12月至2019年5月在本院接受CT引导125I粒子植入治疗的66例局部复发直肠癌患者,所有患者既往接受过手术或外照射放疗。
- 治疗流程包括术前CT定位、计划设计、3D个体化模板打印、CT引导联合3D打印非共面模板辅助粒子植入及术后剂量评估。
主要发现
- 中位随访时间12.2个月(范围2.5-35.9个月)。
- 单枚粒子中位放射性活度0.6 mCi(范围0.43-0.72 mCi),中位粒子数60枚(范围10-175枚)。
- 剂量学参数:D90为140.7±33.1 Gy,D100为90.3±138.6 Gy,V100为91.0±13.3%。
- 85.1%(40/47)患者疼痛缓解;9.1%(6/66)患者出现≥3级严重不良反应,包括肛周皮肤溃疡1例,瘘、放射性直肠炎和肠梗阻各2例。
- 中位总生存时间14.7个月(95%CI:13.0-16.3),中位局部控制时间12.2个月(95%CI:9.1-15.2)。
关键数值与推荐
- 单因素分析显示D90>130 Gy或D100>55 Gy或V100>90%时局部控制时间显著延长。
- 上述剂量学参数均未显著影响总生存时间。
临床怎么用
- 对于术后或外照射放疗后局部复发直肠癌患者,可考虑CT引导联合3D打印非共面模板辅助125I粒子植入作为挽救治疗。
- 治疗计划中应关注D90、D100和V100,D90>130 Gy或D100>55 Gy或V100>90%可能有助于延长局部控制。
局限性
- 本研究为单中心回顾性研究,样本量66例。
- 中位随访时间12.2个月,随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Locally recurrent rectal cancer (LRRC) after surgery or external beam radiotherapy (EBRT) is a serious challenge for which no standard treatment is defined. In the present study, we investigated the feasibility of computed tomography (CT)-guided radioactive 125I seed (RIS) implantation assisted with three-dimensional printing non-coplanar template (3D-PNCT) in LRRC patients who previously received surgery or EBRT. METHODS: Sixty-six patients with LRRC treated by CT-guided RIS implantation in our institute from December 2015 to May 2019 were included. The treatment procedure included: preoperative CT localization, planning design, the printing of 3D individualized template, CT-guided RIS implantation assisted with 3D-PNCT, and postoperative dose evaluation. Therapeutic outcomes including local control (LC) and overall survival (OS) were retrospectively evaluated, as well as side effects. RESULTS: All the patients had previously received surgery or EBRT. The median follow-up time was 12.2 (range, 2.5-35.9) months. The median radioactive activity of a single RIS was 0.6 (range, 0.43-0.72) mCi. The median number of RIS was 60, ranging from 10 to 175. The dosimetric parameters included D90 (140.7 ± 33.1) Gy, D100 (90.3 ± 138.6) Gy, and V100 (91.0 ± 13.3) %. Pain relief was achieved in 85.1% (40/47) of patients. Besides, 9.1% (6/66) of patients had severe side effects (≥grade 3), including perianal skin ulcer in 1 case, fistula, radiation proctitis, and intestinal obstruction each in two cases. Median OS time was 14.7 (95% confidence interval (CI): 13.0-16.3) months, and median LC time was 12.2 (95% CI: 9.1-15.2) months. Univariate analysis revealed that when D90 > 130 Gy or D100 > 55 Gy or V100 > 90%, the LC time was remarkably prolonged. However, none of the parameters significantly affected OS. CONCLUSIONS: CT-guided RIS implantation assisted with 3D-PNCT is an effective and safe salvage treatment strategy for patients with LRRC after EBRT or surgery. D90, D100, and V100 can be used as prognostic predictors. TRIAL REGISTRATION: NCT03890926 .
引用
- Wang L, Wang H, Jiang Y, et al. The efficacy and dosimetry analysis of CT-guided 125I seed implantation assisted with 3D-printing non-co-planar template in locally recurrent rectal cancer. Radiat Oncol. 2020. PMID: 32711542. doi:10.1186/s13014-020-01607-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。